Immunotech Biopharm Ltd (HK:6978) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunotech Biopharm Ltd has announced that foreign ownership restrictions on its partner Yongtai Ruike have been relaxed, allowing Beijing Yongtai to acquire full equity interest in the gene therapy business. The company plans to complete the equity transfer by December 2024, with no expected impact on its overall business operations and financial health. This strategic move is set to streamline operations and retain economic benefits from Yongtai Ruike.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.